VDH COVID-19 Monoclonal Antibody and Therapeutics Bi-Weekly Updates

Virginia Department of Health sent this bulletin at 01/24/2022 09:18 AM EST

mAb newsletter

January 24, 2022

VDH COVID-19 Monoclonal Antibody (mAb) and Therapeutics Bi-Weekly Update

Total Allocations to Monoclonal Antibody Administration Sites (September 27th-January 19th):

mAb 1/21/22

Tracking Information

To track mAb shipments, use the link provided here: https://asdorder.amerisourcebergen.com/btstoreui/trackmyshipment
To track other Therapeutic shipments: log onto HPoP, go to Therapeutic Orders, then click the order you are looking to track
All tracking numbers will populate once doses are shipped

Non-VTrckS Provider Enrollment in VaxMaX

To enroll in VaxMaX as a non-VTrckS provider, follow the link provided here to the VDH mAb webpage: https://www.vdh.virginia.gov/mabs/
Click the blue “Therapeutics Enrollment” button at the top of the page and answer all questions in the REDCap survey for enrollment to be completed
In 24-48 hours, you will receive a verification email that your VaxMaX enrollment was successfully completed and that your HPoP information was uploaded, if applicable
To access the REDCap Survey directly, follow the link provided here: https://redcap.vdh.virginia.gov/redcap/surveys/?s=K9ELDDPDLN

Regen-COV and Bam/Ete will continue to be allocated. Please note that Regen-COV and Bam/Ete are not felt to be effective against the Omicron variant of SARS-CoV-2
Sotrovimab allocations are currently sitting at 1011 a week and are not anticipated to increase before approximately April 2022
Evusheld is available for order
- VDH has approximately 3000 doses available
- Evusheld is not swept by the federal government (unlike the other mAbs)

Both Paxlovid and Molnupiravir are on a two-week allocation cycle (last allocation was 01/10/2022)
- For Paxlovid, all 2080 treatment courses have been allocated
- For Molnupiravir, all 10860 treatment courses have been allocated

Following a recent statement from National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel regarding therapies for COVID-19 Omicron variant, CMS created a HCPCS code J0248 for Veklury (Remdesivir) when administered in an outpatient setting
Medicare Administrative Contractors (MACs) determine Medicare coverage when no national coverage determination exists, including when providers use FDA-approved drugs for indications other than what is on approved label
MACs will determine Medicare coverage for HCPCS code J0248 for Veklury (Remdesivir) administered in an outpatient setting
See CMS COVID-19 Provider Toolkit for additional information

Please find the locator tool here: COVID-19 Treatment Locator
If you are not listed on the Locator Tool and provide appointments to the public, please email covid19therapeutics@vdh.virginia.gov to have your site added

This service is provided to you at no charge by the Virginia Department of Health.